Canopy Growth Corporation (WEED:CA) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong financial performance in the Canadian market and improved adjusted EBITDA. Cost reduction initiatives and free cash flow improvement are positive indicators, despite some challenges in international markets. The Q&A highlighted strategic focus on cost management and potential market growth in Europe and the U.S., with no major capital investments needed. The sentiment is positive, driven by operational improvements and market expansion plans, likely resulting in a stock price increase of 2% to 8%.
Key Financial Performance
Canadian adult-use cannabis net revenue Increased 30% year-over-year in Q2, driven by demand for Claybourne infused pre-rolls and new All-In-One vapes from Tweed and 7ACRES. Stronger relationships with Canadian boards, large accounts, and independent retailers also contributed.
Canadian medical cannabis net revenue Grew 17% year-over-year, supported by growth in patient registrations, larger order volumes, and a broader assortment of products on the Spectrum Therapeutics store.
International cannabis net revenue Declined $3 million year-over-year, primarily due to supply constraints and internal process challenges in Europe, including quality issues and logistics gaps.
Storz & Bickel net revenue $16 million in Q2, up 5% sequentially but down 10% year-over-year. Sequential growth was driven by strong consumer demand for the new VEAZY vaporizer, while the year-over-year decline was due to strong prior-year sales of Venty and Mighty products and favorable German regulatory reforms.
SG&A expenses Declined 13% year-over-year, driven by reductions in headcount and professional fees, partially offset by higher investments in advertising and promotions for new product launches.
Adjusted EBITDA loss $3 million in Q2, compared to a loss of $6 million a year ago. Improvement was driven by a lower cost base and improved margins, partially offset by lower international cannabis revenues and inventory provisions.
Free cash flow Outflow of $19 million in Q2 fiscal '26, down from an outflow of $56 million in the same period last year. Improvement was driven by reduced cash interest payments due to debt paydowns and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Claybourne infused pre-rolls and All-In-One vapes: Net revenue increased 30% year-over-year in Q2, driven by demand for these products.
Storz & Bickel VEAZY Vaporizer: The launch was received with great enthusiasm globally, contributing to sequential quarter-over-quarter revenue growth.
Canadian adult-use cannabis market: Net revenue increased 30% year-over-year in Q2, with a 20% year-over-year distribution increase among Alberta independent retailers.
Canadian medical cannabis market: Net revenue grew 17% year-over-year, with patient registrations up 20% year-over-year and almost tripling since 2021.
SG&A savings program: Delivered over $21 million in annualized savings, surpassing the $20 million target ahead of schedule.
Cost of goods sold: Lowered through streamlined processes, improved yield and quality, and tighter supplier management.
European market stabilization: Dedicated effort to improve supply chain execution, including daily management oversight of logistics and product roadmaps.
Canadian medical cannabis reimbursement changes: Engaging across the country to ensure patient needs remain central amidst proposed government changes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
International Market Performance: Net revenues in international markets declined by $3 million, primarily due to supply constraints and internal process challenges. Flower sourced for sales in Europe did not meet required quality standards, and internal process gaps limited the ability to deliver supply to Germany from Canadian GMP facilities. This underperformance poses a risk to profitability and market presence.
Canadian Medical Cannabis Reimbursement Changes: The Canadian federal government's proposed changes to reduce reimbursement for veterans using prescribed medical cannabis could seriously impact access and quality of care for patients. This could affect the company's revenue and patient trust in the medical cannabis segment.
European Supply Chain Issues: Supply chain execution challenges in Europe, including logistics, product roadmaps, and licensing, have negatively impacted operations. These issues need to be stabilized to prevent further revenue loss and operational inefficiencies.
U.S. Tariffs on Storz & Bickel: U.S. tariffs have created pressure on the profitability of the Storz & Bickel segment. This could impact the segment's financial performance if not mitigated through cost management and operational efficiencies.
Economic Uncertainty in the U.S.: Ongoing economic uncertainty in the U.S. is negatively impacting consumer sentiment, which could challenge year-over-year performance comparisons for the Storz & Bickel segment.
Inventory Provisions: Inventory provisions have partially offset improvements in gross margins, indicating potential inefficiencies in inventory management that could impact profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Canadian adult-use cannabis business: Looking ahead, the company plans to build on its momentum with additional Claybourne innovation, new genetics across its core flower portfolio and PRJ brands, and plans to reach a broader group of consumers later this year. They are also elevating cultivation standards to deliver superior flower quality.
Canadian medical cannabis business: The company aims to deliver a superior patient experience to continue growing this business despite proposed government changes to medical reimbursement.
International markets: The company expects operations to stabilize and begin improving as they exit the fiscal year, with international markets remaining a key part of their path to profitability.
Storz & Bickel: The company expects continued growth through the remainder of the year, driven by the launch of the VEAZY Vaporizer and holiday seasonality. They anticipate stronger performance over the remainder of fiscal '26.
SG&A savings program: The company continues to identify additional savings opportunities while delivering top-line growth.
Profitability: The company is taking steps to lower the cost of goods sold through streamlining processes, smart investments to improve yield and quality, and tighter supplier management.
Free cash flow: For fiscal '26, the company expects significant improvement in free cash flow, driven by reduced cash interest costs, tighter management of working capital, and improved financial performance.
Canada adult-use channel: The company expects improved performance over the remainder of fiscal '26, driven by a robust innovation pipeline and tight alignment with cannabis boards and retailers.
Canada medical cannabis: Excluding potential changes to medical cannabis reimbursement, the company expects top-line growth in the back half of fiscal '26.
International markets cannabis: The company expects revenue in Europe to remain consistent with Q2 levels, with growth expected as they exit the fiscal year. In Australia, they anticipate sequential growth in the second half of the fiscal year due to new product introductions.
Storz & Bickel gross margins: The company expects sequential improvement over the remainder of fiscal '26, driven by top-line growth and cost-saving initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What changes are needed to reopen the international pipeline and will the solution be more costly than the prior product pass into the German market?
A:The company is retooling its route to market to satisfy European demand from Canadian GMP facilities without increasing the cost of the flower. They are expanding the number of strains grown for Europe and broadening their distribution retail offering.
Q:Why was the ATM used aggressively in 2Q and what is the outlook for future issuance?
A:The ATM was used to ensure optimal capital structure balancing cost efficiency with financial flexibility. The company has the program in place for optionality but refrains from speculating on future usage.
Q:Are there plans to increase verticality in the supply chain for international markets due to supply chain issues?
A:The company is currently relying on its Canadian GMP facilities to supply international markets and has sufficient capacity. They are not ruling out third-party flower in the future but are focusing on their own grown flower for now.
Q:What is the timeline for achieving profitability and updates on key levers for positive EBITDA?
A:The company is focused on cost savings and improving adjusted EBITDA performance but refrains from providing a specific timeline. Positive adjusted EBITDA remains a priority, and they are retooling Europe to support this goal.
Q:Does the company foresee any need for significant investment in additional capacity given the growth in cannabis platforms?
A:The company believes its current facilities, with limited smart investments to improve yield and quality, are sufficient to meet growth targets. No significant additional capital investment is expected.
Q:What are the capital allocation priorities now that the company has significantly reduced debt?
A:With $300 million in cash and no near-term debt obligations, the company is evaluating potential accretive investment opportunities while focusing on stabilizing the business and mitigating risks.
Q:Can you provide more details on the vape launch and the U.S. business, including Canopy USA and Acreage?
A:The company is seeing strong early results with All-In-One vapes and plans to expand into live resin and other products. Canopy USA operates independently with no financial guarantees from Canopy Growth. Recent financing was secured for Canopy USA, and they are focused on execution and integration of their U.S. businesses.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for achieving profitability and refrained from speculating on future ATM issuance. They also used vague language regarding the U.S. business, particularly in terms of financial support and integration details for Canopy USA and Acreage.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACRES relationship
Alberta retailer
BC Georgia
Bickel action
Bickel commitment
Bickel launch
Conference Director
DOJA bucking
Europe quality
Europe supply
Flower sale
GMP facility
Georgia site
Germany GMP
Officer Stewart
PRJ brand
SGA saving
Spectrum patient
Stewart market
VEAZY Vaporizer
access
account
board
care
consistency
cultivation
government
momentum adult
patient experience
period
plan
profitability
provider
reimbursement
reliability
service
standard
use cannabis
veteran
CGC Transcript
Canopy Growth Corporation (WEED:CA) Q4 2026 Earnings Call Transcript
Neutral6-15
Canopy Growth Corporation (WEED:CA) Q3 2026 Earnings Call Transcript
Unknown2-6
The earnings call presents a mixed picture: positive elements include a 22% increase in international cannabis revenue and reduced SG&A expenses. However, concerns arise from declining gross margins and unclear guidance on achieving positive EBITDA. The Q&A reveals uncertainties about veteran pricing impacts and cash utilization. The absence of a clear market cap further complicates predictions. Overall, the sentiment is balanced, resulting in a neutral outlook for the stock price movement over the next two weeks.
Canopy Growth Corporation (WEED:CA) Q2 2026 Earnings Call Transcript
Positive11-7
The earnings call revealed strong financial performance in the Canadian market and improved adjusted EBITDA. Cost reduction initiatives and free cash flow improvement are positive indicators, despite some challenges in international markets. The Q&A highlighted strategic focus on cost management and potential market growth in Europe and the U.S., with no major capital investments needed. The sentiment is positive, driven by operational improvements and market expansion plans, likely resulting in a stock price increase of 2% to 8%.
Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript
Unknown8-8
The earnings call reflects mixed signals. Positive aspects include a 24% revenue increase and cost reduction initiatives, but challenges like declining margins, debt burden, and soft demand in key markets offset them. The Q&A highlighted gross margin improvements and potential growth in Europe, yet concerns about U.S. rescheduling and Polish supply issues persist. Overall, the financial performance and strategic outlook are balanced, leading to a neutral sentiment.
CGC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
